Laboratorios Farmaceuticos Rovi, S.A.

LABFFOTCHealthcare● Active

$90.61

+$0.00(+0.00%)

Market Cap$4.6B

P/E Ratio—

52W High$90.61

52W Low$90.61

Avg Volume53.6

Open$90.61

Beta0.22

Cash on Hand Financials Revenue

Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

LABFF · cash on hand · updated Dec 31, 2025

Core cash position

as of Dec 31, 2025

Cash & Short-Term Investments (CCE + ST Investments)

$97.9M▲ +257.3% vs prior year

FY · as of Dec 31, 2025 · Reported in EUR

Cash & Cash Equiv. (CCE)

$97.9M

cashAndCashEquivalents

Short-Term Investments

shortTermInvestments

YoY Change vs Prior Year

+257.3%

vs prior fiscal year

Latest Quarter

$97.8M

Q1 2026

Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in EUR

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash vs Debt · Balance Sheet Health

Cash & ST Investments$97.9MCash on Hand

Total Debt$146.0MTotal Debt

Net Cash / Net Debt−$48.1MNet Debt Position

Cash vs Debt Ratio

Cash 40%Laboratorios Farmaceuticos Rovi, S.A. cash as % of market cap: 2.11%% · MCap $5BDebt 60%

Laboratorios Farmaceuticos Rovi, S.A. carries a net debt position of $48.1M. Total debt ($146.0M) exceeds cash on hand ($97.9M). Laboratorios Farmaceuticos Rovi, S.A. cash vs debt ratio: 40% cash / 60% debt.

Net Cash = Cash & ST Investments − Total Debt$97.9M − $146.0M = −$48.1M

Cash on hand history

annual cash on hand trend · Cash & Short-Term Investments

YoY Increase

YoY Decrease

Latest Year

LABFF annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

LABFF cash & short-term investments history

DatePeriodCash & ST InvestmentsYoY Change

Dec 31, 2025LatestFY$97.9M+257.3%

Dec 31, 2024FY$27.4M+7.8%

Dec 31, 2023FY$25.4M-79.6%

Dec 31, 2022FY$124.9M+26.2%

Dec 31, 2021FY$99.0M+86.3%

LABFF cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

LABFF vs peers · cash on hand

#CompanyCash & ST Inv.Market CapCash/MCapRelative

UnitedHealth Group Incorporated

Eli Lilly and Company

Laboratorios Farmaceuticos Rovi, S.A.YOU

LABFF

$97.9M$5B2.1%

Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Laboratorios Farmaceuticos Rovi, S.A. (LABFF) cash on hand as of December 31, 2025 is $97.9M, comprising $97.9M in cash and cash equivalents (CCE) plus $0 in short-term investments — reported as Laboratorios Farmaceuticos Rovi, S.A. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Laboratorios Farmaceuticos Rovi, S.A. cash reserves or cash position.

Laboratorios Farmaceuticos Rovi, S.A. annual cash on hand history shows increased +257.3% in 2025: increased +257.3% in 2025. Laboratorios Farmaceuticos Rovi, S.A. cash reserves in 2025 reflect the company's capital allocation strategy.

Laboratorios Farmaceuticos Rovi, S.A. carries total debt of $146.0M against cash of $97.9M, resulting in a net debt position of -$48.1M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.

Financial statements Free cash flow Net income Revenue Market cap P/E ratio Earnings Price history

Frequently asked questions

LABFF cash on hand · 5 questions

As of December 31, 2025, Laboratorios Farmaceuticos Rovi, S.A. (LABFF) has $97,939,303 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $97,939,303 in cash and cash equivalents (CCE) plus $0 in short-term investments. Latest quarter (March 31, 2026): $97,760,793. Data sourced from the annual 10-K filing via FMP.

LABFF cash on handLABFF cash reservesLABFF cash 2025how much cash does LABFF have

▸ Source: FMP /balance-sheet-statement · US GAAP · Laboratorios Farmaceuticos Rovi, S.A. · Laboratorios Farmaceuticos Rovi, S.A. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025